Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis. METHODS: In a 12-month, phase 2 trial, we assessed the efficacy and safety of four different oral doses of the tyrosine kinase inhibitor BIBF 1120 as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Secondary end points included acute exacerbations, quality of life (measured with the St. George's Respiratory Questionnaire [SGRQ]), and total lung capacity. RESULTS: A total of 432 patients underwent randomization to receive one of four doses of BIBF 1120 (50 mg once a day, 50 mg twice a day, 100 mg twice a day, or 150 mg twice a day) or placebo. In the group receiving 150 mg of BIBF 1120 twice a day, FVC declined by 0.06 liters per year, as compared with 0.19 liters per year in the placebo group, a 68.4% reduction in the rate of loss with BIBF 1120 (P = 0.06 with the closed testing procedure for multiplicity correction; P = 0.01 with the hierarchical testing procedure). This dose also resulted in a lower incidence of acute exacerbations, as compared with placebo (2.4 vs. 15.7 per 100 patient-years, P = 0.02) and a small decrease in the SGRQ score (assessed on a scale of 0 to 100, with lower scores indicating better quality of life) as compared with an increase with placebo (-0.66 vs. 5.46, P = 0.007). Gastrointestinal symptoms (which led to more discontinuations in the group receiving 150 mg twice a day than in the placebo group) and increases in levels of liver aminotransferases were more frequent in the group receiving 150 mg of BIBF 1120 twice daily than in the placebo group. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, BIBF 1120 at a dose of 150 mg twice daily, as compared with placebo, was associated with a trend toward a reduction in the decline in lung function, with fewer acute exacerbations and preserved quality of life. (Funded by Boehringer Ingelheim; ClinicalTrials.gov number, NCT00514683 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Bayesian approach incorporated dynamic borrowing of historical placebo data from several external IPF trials, including the ASCEND, INPULSIS, and TOMORROW studies (Figures E2 and E3).2,3,13”
From Deupirfenidone Compared with Pirfenidone and Placebo in Idiopathic Pulmonary Fibrosis (ELEVATE-IPF): a Phase 2b Randomized Placebo-Controlled Trial (2026) · cites this paper as [13]
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Acute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationBois, R. M. D., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201007-1179oc · Cited by 465
Self-citation
Cited by
Items 401–500 of 1,000
Pharmacological treatment of idiopathic pulmonary fibrosis: an update
Spagnolo, P., Wells, A. U., & Collard, H. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.001 · Cited by 33
Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease
Gibson, C. D., Kugler, M. C., Deshwal, H., Munger, J. S., & Condos, R. (2020) · Lung · doi:10.1007/s00408-020-00370-1 · Cited by 32
Kato, M., Sasaki, S., Tateyama, M., Arai, Y., Motomura, H., Sumiyoshi, I., Ochi, Y., Watanabe, J. A., Ihara, H., Togo, S., et al. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s284819 · Cited by 35
Skandamis, A., Kani, C., Markantonis, S. L., & Souliotis, K. N. (2019) · Journal of Drug Assessment · doi:10.1080/21556660.2019.1597726 · Cited by 34
Caminati, A., Madotto, F., Conti, S., Cesana, G., Mantovani, L. G., & Harari, S. A. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02651-w · Cited by 32
Development of nintedanib nanosuspension for inhaled treatment of experimental silicosis
da Silva, L. H. A., Vieira, J. B., Cabral, M. R., Antunes, M. A., Lee, D., Cruz, F. F., Hanes, J. S., Rocco, P. R. M., Morales, M. M., & Suk, J. S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10401 · Cited by 34
Kalash, R., Epperly, M. W., Goff, J. P., Dixon, T. M., Sprachman, M. M., Zhang, X., Shields, D. S., Cao, S., Franicola, D., Wipf, P., et al. (2013) · Radiation Research · doi:10.1667/rr3233.1 · Cited by 30
Treatment of rapidly progressive systemic sclerosis: current and futures perspectives
Mendoza, F. A., Mansoor, M., & Jiménez, S. A. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1114454 · Cited by 33
Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis
Spagnolo, P., & Wuyts, W. A. (2017) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000405 · Cited by 35
Pirfenidone and Nintedanib for Treatment of Idiopathic Pulmonary Fibrosis
Sathiyamoorthy, G., Sehgal, S., & Ashton, R. W. (2017) · Southern Medical Journal · doi:10.14423/smj.0000000000000655 · Cited by 30
Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
Self-citationThe safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis
Cottin, V. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338268 · Cited by 31
Quintela-Fandiño, M., Apala, J. V., Malón, D., Mouron, S. A., Hornedo, J., González‐Cortijo, L., Colomer, R., & Guerra, J. A. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1152-x · Cited by 30
Campo, A., González‐Ruiz, J. M., Andreu, E. J., Alcaide, A. B., Ocón, M. D. M., de-Torres, J. P., Pueyo, J. C., Cordovilla, R., Villarón, E. M., Sanchez-Guijo, F. M., et al. (2021) · ERJ Open Research · doi:10.1183/23120541.00773-2020 · Cited by 31
Kamiya, H., & Panlaqui, O. M. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01502-w · Cited by 30
López-Matencio, J. M. S., Gómez, M., Vicente‐Rabaneda, E. F., González-Gay, M. Á., Ancochea, J., & Castañeda, S. (2021) · Pharmaceuticals · doi:10.3390/ph14080819 · Cited by 31
Khan, F. A., Stewart, I. D., Moss, S., Fabbri, L., Robinson, K. A., Johnson, S., & Jenkins, G. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202109-2091oc · Cited by 32
Murray, L. A., Rubinowitz, A. N., & Herzog, E. L. (2012) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283588de4 · Cited by 33
Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme
Valenzuela, C., Torrisi, S. E., Kahn, N. C., Quaresma, M., Stowasser, S., & Kreuter, M. (2020) · Respiratory Research · doi:10.1186/s12931-019-1269-6 · Cited by 32
Piotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Evolution and treatment of idiopathic pulmonary fibrosis
Torrisi, S. E., Kahn, N. C., Vancheri, C., & Kreuter, M. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104025 · Cited by 29
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
Jo, H. E., Glaspole, I., Goh, N., Hopkins, P. M. A., Moodley, Y., Reynolds, P. N., Chapman, S., Walters, E. H., Zappala, C., Allan, H., et al. (2019) · Respirology · doi:10.1111/resp.13427 · Cited by 28
Recent advances in connective tissue disease related interstitial lung disease
Suzuki, A., Kondoh, Y., & Fischer, A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1335600 · Cited by 30
Kindlin-2 Acts as a Key Mediator of Lung Fibroblast Activation and Pulmonary Fibrosis Progression
Zhang, P., Wang, J., Luo, W., Yuan, J., Cui, C., Guo, L., & Wu, C. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0320oc · Cited by 29
Understanding idiopathic pulmonary fibrosis - Clinical features, molecular mechanism and therapies
Suri, G. S., Kaur, G., Jha, C. K., & Tiwari, M. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111473 · Cited by 31
Plumbagin attenuates Bleomycin-induced lung fibrosis in mice
Mehdizadeh, S., Taherian, M., Bayati, P., Mousavizadeh, K., Pashangzadeh, S., Anisian, A., & Mojtabavi, N. (2022) · Allergy Asthma and Clinical Immunology · doi:10.1186/s13223-022-00734-7 · Cited by 28
Behr, J., Hoeper, M. M., Kreuter, M., Klotsche, J., Wirtz, H., & Pittrow, D. (2014) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2013-000010 · Cited by 28
Nintedanib: A Novel Therapeutic Approach for Idiopathic Pulmonary Fibrosis
Dimitroulis, J. (2014) · Respiratory Care · doi:10.4187/respcare.03023 · Cited by 30
Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
Marzin, K., Kretschmar, G., Luedtke, D., Kraemer, S., Kuelzer, R., Schlenker‐Herceg, R., Schmid, U., Schnell, D., & Dallinger, C. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1025 · Cited by 28
Systemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
Mirsaeidi, M. S., Barletta, P., & Glassberg, M. K. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00248 · Cited by 33
Zhang, Y., MacKenzie, B., Koleng, J. J., Maier, E., Warnken, Z. N., & Williams, R. O. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b01085 · Cited by 27
Sabir, M. W., Farhan, M., Almalki, N. S., Alnfiai, M. M., & Sampedro, G. A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1282200 · Cited by 30
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Lee, J. S., & Collard, H. R. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-682-5_17 · Cited by 27
Rinciog, C., Diamantopoulos, A., Gentilini, A., Bondue, B., Dahlqvist, C., Froidure, A., Wuyts, W. A., & Soulard, S. (2020) · PharmacoEconomics - Open · doi:10.1007/s41669-019-00191-w · Cited by 27
Shochet, G. E., Pham, S., Beck, S., Naiel, S., Mekhael, O., Revill, S. D., Hayat, A. I., Vierhout, M., Bardenstein-Wald, B., Shitrit, D., et al. (2020) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2020.101933 · Cited by 28
Chen, C., Lin, H.-C., Wang, Y., Wang, C., Lin, Y. S., & Lai, C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251636 · Cited by 31
Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
de Andrade, J. A., Neely, M. L., Hellkamp, A. S., Culver, D. A., Kim, H. J., Liesching, T. N., Lobo, L. J., Ramaswamy, M., Safdar, Z., Bender, S. D., et al. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.03.003 · Cited by 28
Ruaro, B., Salotti, A., Reccardini, N., Kette, S., Re, B. D., Nicolosi, S., Zuccon, U., Confalonieri, M., Mondini, L., Pozzan, R., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17010119 · Cited by 30
Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy
Jones, M. G., Fletcher, S., & Richeldi, L. (2013) · Respiration · doi:10.1159/000356958 · Cited by 28
Self-citationNintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis
Fukihara, J., & Kondoh, Y. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2016.1249854 · Cited by 27
Body size‐adjusted dose analysis of pirfenidone in patients with interstitial pneumonia
Uehara, M., Enomoto, N., Oyama, Y., Suzuki, Y., Kono, M., Furuhashi, K., Fujisawa, T., Inui, N., Nakamura, Y., & Suda, T. (2017) · Respirology · doi:10.1111/resp.13145 · Cited by 28
Harris, W. T., Kelly, D. R., Zhou, Y., Wang, D., MacEwen, M. W., Hagood, J. S., Clancy, J. P., Ambalavanan, N., & Sorscher, E. J. (2013) · PLoS ONE · doi:10.1371/annotation/d0132de3-56ca-4258-9119-bdab0ceb2cff · Cited by 28
Development of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 28
Self-citationAn update on emerging drugs for the treatment of idiopathic pulmonary fibrosis
Aryal, S., & Nathan, S. D. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1471465 · Cited by 29
Bárczi, E., Starobinski, L., Kolonics-Farkas, A. M., Eszes, N., Bohács, A., Vašáková, M., Hejduk, K., & Müller, V. (2019) · Advances in Therapy · doi:10.1007/s12325-019-00906-9 · Cited by 27
Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., Furuhashi, K., et al. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01587-3 · Cited by 27
Boutel, M., Boutou, A., Pitsiou, G., Garyfallos, A., & Dimitroulas, T. (2023) · Diagnostics · doi:10.3390/diagnostics13071221 · Cited by 29
Management of idiopathic pulmonary fibrosis in France: A survey of 1244 pulmonologists
Cottin, V., Cadranel, J. L., Crestani, B., Dalphin, J., Delaval, P., Israël‐Biet, D., Kessler, R., Reynaud‐Gaubert, M., Valeyre, D., Wallaert, B., et al. (2013) · Respiratory Medicine · doi:10.1016/j.rmed.2013.11.017 · Cited by 30
Lv, M., Liu, Y., Ma, S., & Yu, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0111 · Cited by 28
Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
Wongkarnjana, A., Scallan, C. J., & Kolb, M. R. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000712 · Cited by 26
The evolving pharmacotherapy of pulmonary fibrosis
Lota, H., & Wells, A. U. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758250 · Cited by 25
Cottin, V., Crestani, B., Cadranel, J. L., Cordier, J. F., Marchand-Adam, S., Prévot, G., Wallaert, B., Bergot, E., Camus, P., Dalphin, J., et al. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.07.018 · Cited by 25
Troy, L. K., Grainge, C., Corte, T. J., Williamson, J., Vallely, M. P., Cooper, W. A., Mahar, A. M., Lai, S., Mulyadi, E., Torzillo, P. J., et al. (2019) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2019-000443 · Cited by 39
Self-citationKalafatis, D., Löfdahl, A., Näsman, P., Dellgren, G., Wheelock, Å. M., Elowsson, L., Sköld, M. C., & Westergren‐Thorsson, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413421 · Cited by 25
Dempsey, T. M., Thao, V., Moriarty, J. P., Borah, B. J., & LIMPER, A. H. (2022) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01811-0 · Cited by 25
Ye, Y., Hubbard, R., Li, G. H., Ho, S., Sing, C., Cheung, C. L., & Lam, D. C. L. (2022) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.5421 · Cited by 27
Wang, X., Gadhave, D. G., Chauhan, G., & Gupta, V. (2023) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2023.105233 · Cited by 25
Shlobin, O. A., Shen, E., Wort, S. J., Piccari, L., Scandurra, J., Hassoun, P. M., Nikkho, S. M., & Nathan, S. D. (2024) · Pulmonary Circulation · doi:10.1002/pul2.12310 · Cited by 26
Emerging therapeutic interventions for idiopathic pulmonary fibrosis
Chakraborty, S., Chopra, P., Ambi, S. V., Dastidar, S. G., & Ray, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.913569 · Cited by 29
Protective Effect of Atazanavir Sulphate Against Pulmonary FibrosisIn VivoandIn Vitro
Song, S., Ji, Y., Zhang, G., Zhang, X., Li, B., Li, D., & Jiang, W. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12871 · Cited by 27
Tackling MARCKS‐PIP3 circuit attenuates fibroblast activation and fibrosis progression
Yang, D. C. H., Li, J., Xu, J., Oldham, J. M., Phan, S. H., Last, J. A., Wu, R., & Chen, C. (2019) · The FASEB Journal · doi:10.1096/fj.201901705r · Cited by 28
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Trachalaki, A., Irfan, M., & Wells, A. U. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1822326 · Cited by 26
Homma, S. A., Suda, T., Hongo, Y., Yoshida, M., Hiroi, S., Iwasaki, K., Takeshima, T., & Kondoh, Y. (2022) · Respiratory Investigation · doi:10.1016/j.resinv.2022.07.004 · Cited by 26
Is It Idiopathic Pulmonary Fibrosis or Not?
Salvatore, M. M., Ishikawa, G., & Padilla, M. L. (2018) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2018.01.170288 · Cited by 24
Yamakawa, H., Kitamura, H., Takemura, T., Ikeda, S., Sekine, A., Baba, T., Iwasawa, T., Hagiwara, E., Sato, S., & Ogura, T. (2018) · Respirology · doi:10.1111/resp.13313 · Cited by 24
Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study
Abe, M., Tsushima, K., Sakayori, M., Suzuki, K., Ikari, J., Terada, J., & Tatsumi, K. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s179427 · Cited by 25
Cottin, V., Bonniaud, P., Cadranel, J. L., Crestani, B., Jouneau, S., Marchand-Adam, S., Nunès, H., Wémeau-Stervinou, L., Bergot, E., Blanchard, É., et al. (2022) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.01.005 · Cited by 27
Huang, T., Kuo, C., Chen, C., Tseng, Y., Wu, C., & Lin, S. (2021) · BMC Pulmonary Medicine · doi:10.1186/s12890-021-01530-6 · Cited by 24
Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Ancochea, J., Bollo, E., Fernández‐Fabrellas, E., Franquet, T., Molina‐Molina, M., Montero, M. A., & Serrano‐Mollar, A. (2013) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2013.06.003 · Cited by 45
New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?
Wijsenbeek, M. S., van Manen, M. J. G., & Bonella, F. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000294 · Cited by 24
Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012
Raghu, G. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61256-2 · Cited by 24
Self-citationGuidelines for the selection of lung-transplant candidates
Shah, P. D., & Orens, J. B. (2012) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e328357d898 · Cited by 27
Bridges, J. F. P., Paly, V. F., Barker, E. R., & Kervitsky, D. J. (2014) · Patient · doi:10.1007/s40271-014-0081-0 · Cited by 27
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease
Mehrad, B., & Strieter, R. M. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s22 · Cited by 29
Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation
ten Klooster, L., Nossent, G. D., Erp, J. M. K., van Kessel, D. A., Oudijk, E. D., van de Graaf, E. A., Luijk, B., Hoek, R. A. S., van den Blink, B., van Hal, P. T., et al. (2015) · Lung · doi:10.1007/s00408-015-9794-7 · Cited by 23
Safety of nintedanib before lung transplant: an Italian case series
Balestro, E., Solidoro, P., Parigi, P., Boffini, M., Lucianetti, A., & Rea, F. (2018) · Respirology Case Reports · doi:10.1002/rcr2.312 · Cited by 25
Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update
Wongkarnjana, A., Yanagihara, T., & Kolb, M. R. J. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1673733 · Cited by 25
Aschner, Y., & Downey, G. P. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2018-0049tr · Cited by 25
Advances in idiopathic pulmonary fibrosis diagnosis and treatment
Liu, H., Shen, J., & He, C. (2025) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2025.02.001 · Cited by 23
Behr, J., Bonella, F., Frye, B. C., Günther, A., Hagmeyer, L., Henes, J. C., Klemm, P., Koschel, D., Kreuter, M., Leuschner, G., et al. (2023) · Pneumologie · doi:10.1055/a-1983-6796 · Cited by 26
Self-citationPharmacotherapies in Dupuytren Disease: Current and Novel Strategies
Lambi, A. G., Popoff, S. N., Benhaim, P., & Barbe, M. F. (2023) · The Journal Of Hand Surgery · doi:10.1016/j.jhsa.2023.02.003 · Cited by 22
Walking the path of treatable traits in interstitial lung diseases
Amati, F., Spagnolo, P., Ryerson, C. J., Oldham, J. M., Gramegna, A., Stainer, A., Mantero, M., Sverzellati, N., Lacedonia, D., Richeldi, L., et al. (2023) · Respiratory Research · doi:10.1186/s12931-023-02554-8 · Cited by 24
Self-citationZhao, R., Xie, B., Wang, X., Zhang, X., Ren, Y., Wang, C., & Dai, H. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102287 · Cited by 24
Schmid, U., Liesenfeld, K., Fleury, A., Dallinger, C., & Freiwald, M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3452-0 · Cited by 22
Anticancer drug treatment for advanced lung cancer with interstitial lung disease
Otsubo, K., Okamoto, I., Hamada, N., & Nakanishi, Y. (2018) · Respiratory Investigation · doi:10.1016/j.resinv.2018.03.002 · Cited by 22
Zhang, J., Li, Q., Shao, Q., Song, J., Zhou, B., & Shu, P. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27045 · Cited by 22
Treatment strategies for idiopathic interstitial pneumonias
Wells, A. U., Kokosi, M. A., & Karagiannis, K. (2014) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000085 · Cited by 23
Hamama, S., Delanian, S. E., Monceau, V., & Vozenin, M. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s13 · Cited by 22
The Effect of Nintedanib in Post-COVID-19 Lung Fibrosis: An Observational Study
Saiphoklang, N., Patanayindee, P., & Ruchiwit, P. (2022) · Critical Care Research and Practice · doi:10.1155/2022/9972846 · Cited by 30
Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols
Patel, H., Shah, J. R., Patel, D., Avanthika, C., Jhaveri, S., & Gor, K. (2022) · Disease-a-Month · doi:10.1016/j.disamonth.2022.101484 · Cited by 25
Improved Survival of IPF patients Treated With Antifibrotic Drugs Compared With Untreated Patients
Platenburg, M. G. J. P., van Moorsel, C. H. M., Wiertz, I. A., van der Vis, J. J., Vorselaars, A. D. M., Veltkamp, M., & Grutters, J. C. (2023) · Lung · doi:10.1007/s00408-023-00628-4 · Cited by 22
Liu, H., Huang, Z., Li, H., Zhang, Q., Tan, X., Fangzheng, L., & Li, S. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s83055 · Cited by 23
Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?
Antoniu, S. A. (2012) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-7-41 · Cited by 21
Wang, X., Gao, J., Zhao, M., Zhu, H.-X., Tian, Y., Li, R., Jiang, X., Yu, L., Tian, J., & Cui, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3284 · Cited by 21
Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
Bonella, F., Cottin, V., Valenzuela, C., Wijsenbeek, M. S., Voß, F., Rohr, K. B., Stowasser, S., & Maher, T. M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02145-x · Cited by 21
Achyut, B. R., Shankar, A., Iskander, A., Ara, R., Knight, R. A., Scicli, A. G., & Arbab, A. S. (2016) · Cancer Biology & Therapy · doi:10.1080/15384047.2016.1139243 · Cited by 20
Nakamura, Y., & Shimizu, Y. (2023) · Cells · doi:10.3390/cells12040548 · Cited by 22
Kamio, K., Azuma, A., Ohta, K., Sugiyama, Y., Nukiwa, T., Kudoh, S., & Mizushima, T. (2014) · BMC Pulmonary Medicine · doi:10.1186/1471-2466-14-86 · Cited by 20
Cordeiro, C. R., Campos, P., Carvalho, L., Borba, A., Clemente, S., Freitas, S., Furtado, S. T., Jesus, J. M., Leal, C., Marqués, J., et al. (2017) · Revista Portuguesa de Pneumologia · doi:10.1016/j.rppnen.2017.05.005 · Cited by 23
Metadata
- Authors
- Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., Brun, M., Gupta, A., Juhel, N., Klüglich, M., & du Bois, R. M.
- Affiliations
- University of Modena and Reggio Emilia (IT)
- Ruhrlandklinik (DE)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Michigan Medicine (US)
- Duke Medical Center (US)
- University of Washington (US)
- Boehringer Ingelheim (France) (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-09-22
- Volume
- 365
- Issue
- 12
- Pages
- 1079-1087
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2152974152
- Cited by
- 1,157
- References
- 22
- Citations by year
- 2026: 32 · 2025: 50 · 2024: 79 · 2023: 74 · 2022: 83 · 2021: 86 · 2020: 73 · 2019: 72 · 2018: 91 · 2017: 102 · 2016: 88 · 2015: 100 · 2014: 71 · 2013: 80 · 2012: 61
- FWCI
- 60.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, nintedanib, tyrosine kinase inhibitors, forced vital capacity decline, lung fibrosis progression, acute exacerbation, quality of life, gastrointestinal adverse effects, liver aminotransferases, dose comparison, St George's Respiratory Questionnaire, total lung capacity, drug safety and efficacy
- MeSH terms
- Adult, Aged, Alanine Transaminase, Aspartate Aminotransferases, Enzyme Inhibitors, Female, Humans, Indoles, Liver, Male, Middle Aged, Protein-Tyrosine Kinases, Vital Capacity, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.